Day

November 7, 2018
IV Administration BMC

Considerations On the Regulatory Status of IV Administration of BMC: A Useful Shot in the Arm? Part One

During a presentation at the recently concluded MedRebels conference, Dr. Don Buford indicated that there were no “homologus use” indications associated with IV infusion of autologous bone marrow concentrate (BMC). He made this point, in part, because of language the FDA has included in 21 CFR 1271.3 as follows: The following articles are not considered...
Read More